Hub : Traits :

Past tobacco smoking

150 significantly associated models · 49 unique genes.

Significant Loci

#	chr	p0	p1	# assoc genes	# joint genes	best TWAS P	best SNP P	cond SNP P	% var exp	joint genes
1	2	44448632	45864710	1	1	4.3e-12	1.0e-11	1.0e+00	100	RP11-89K21.1
2	2	47224927	48727280	1	1	1.5e-07	8.6e-07	2.0e-02	78	MSH6
3	3	49634594	51032607	1	1	1.9e-07	9.2e-06	3.3e-01	95	NAT6
4	3	84317575	86808226	1	1	8.7e-17	2.1e-17	3.9e-02	94	CADM2
5	4	57080198	58531645	3	1	3.1e-08	2.3e-08	9.7e-02	91	REST
6	5	86867897	88427942	1	1	1.1e-07	5.0e-07	3.8e-01	97	TMEM161B-AS1
7	6	36751245	38162310	1	1	1.1e-07	1.3e-07	2.0e-02	80	CCDC167
8	6	110588546	112621834	5	3	1.3e-15	9.0e-18	3.4e-01	99	C6orf3 GTF3C6 RP5-1112D6.4
9	6	157013426	158435623	1	1	6.4e-08	6.8e-08	1.0e+00	100	TMEM242
10	7	1363454	1876081	1	1	1.4e-08	7.8e-09	2.4e-03	72	KIAA1908
11	7	2646223	5003373	1	1	4.5e-10	4.6e-11	2.7e-02	89	SDK1
12	7	98341025	99751521	1	1	9.3e-08	5.4e-07	7.1e-01	100	CPSF4
13	9	127218258	128824378	2	1	6.6e-08	2.2e-07	9.4e-03	75	PRPS1P2
14	10	103527782	105897979	14	2	1.4e-14	4.3e-13	5.9e-01	99	C10orf32 TMEM180
15	11	112135760	113846006	1	1	4.7e-09	5.1e-36	1.2e-28	21	NCAM1
16	12	111193499	113137832	3	1	3.2e-08	2.1e-11	1.7e-05	59	ATXN2
17	15	66850204	68789191	3	1	8.4e-09	2.6e-08	7.0e-02	89	MAP2K5
18	16	30347731	31720486	1	1	2.1e-07	7.6e-05	5.5e-03	51	STX1B
19	16	69062879	70473934	2	1	4.8e-10	2.7e-09	6.1e-01	99	NOB1
20	17	1517914	2918626	1	1	1.4e-07	5.2e-07	1.0e+00	100	SRR
21	18	20393480	21863589	1	1	2.4e-07	3.2e-07	1.4e-01	92	NPC1
22	20	30591354	32029439	1	1	2.9e-07	1.5e-06	1.9e-04	40	COMMD7

Pleiotropic Associations

Trait	chisq ratio	# genes⁺	# genes⁺⁺	% genes⁺⁺	corr	corr P	genes
Smoking Status	16.16	23	17	37.8	-0.99	7.3e-18	C10orf32 C6orf3 CADM2 CCDC167 COMMD7 CPSF4 GTF3C6 KIAA1908 MAP2K5 MSH6 NAT6 NCAM1 NOB1 PRPS1P2 REST RP11-89K21.1 RP5-1112D6.4 SDK1 SRR STX1B TMEM161B-AS1 TMEM180 TMEM242
Ever smoked	16.05	25	11	24.4	-0.99	1.8e-24	ATXN2 C10orf32 C6orf3 CADM2 CCDC167 COMMD7 CPSF4 GTF3C6 KIAA1908 MAP2K5 MSH6 NAT6 NCAM1 NOB1 NPC1 PRPS1P2 REST RP11-89K21.1 RP5-1112D6.4 SDK1 SRR STX1B TMEM161B-AS1 TMEM180 TMEM242
Smoking status: Previous	15.57	23	6	13.3	-0.99	8.2e-21	ATXN2 C10orf32 C6orf3 CADM2 CCDC167 COMMD7 GTF3C6 KIAA1908 MAP2K5 MSH6 NAT6 NCAM1 NOB1 NPC1 REST RP11-89K21.1 RP5-1112D6.4 SDK1 SRR STX1B TMEM161B-AS1 TMEM180 TMEM242
Blood Eosinophil Count	5.35	3	2	4.4	0.00	1.0e+00	ATXN2 NAT6 REST
Smoking status: Current	5.21	6	2	4.4	-0.97	1.8e-03	C10orf32 CADM2 GTF3C6 NCAM1 PRPS1P2 RP11-89K21.1
Current tobacco smoking	4.95	5	2	4.4	-0.96	1.0e-02	C10orf32 GTF3C6 NCAM1 PRPS1P2 RP11-89K21.1
Risk taking	4.59	4	1	2.2	-0.95	5.1e-02	C10orf32 CADM2 RP11-89K21.1 TMEM242
Worrier / anxious feelings	4.57	5	1	2.2	0.99	2.0e-03	C10orf32 CADM2 GTF3C6 STX1B TMEM180
Comparative body size at age 10	4.32	6	5	11.1	0.03	9.6e-01	CADM2 MAP2K5 NAT6 NPC1 SRR TMEM161B-AS1
Maternal smoking around birth	4.30	3	1	2.2	0.00	1.0e+00	C10orf32 GTF3C6 RP5-1112D6.4
BMI	4.23	10	6	13.3	-0.45	1.9e-01	CADM2 CPSF4 GTF3C6 MAP2K5 NAT6 NOB1 NPC1 SRR STX1B TMEM161B-AS1
Body mass index (BMI)	4.19	11	6	13.3	-0.53	9.5e-02	C6orf3 CADM2 CPSF4 GTF3C6 MAP2K5 NAT6 NOB1 NPC1 SRR STX1B TMEM161B-AS1
Nervous feelings	4.08	5	1	2.2	0.82	9.1e-02	C10orf32 CADM2 PRPS1P2 SRR TMEM180
Worry (Nagel 2018)	3.96	5	1	2.2	0.79	1.1e-01	C10orf32 CADM2 PRPS1P2 STX1B TMEM180
Leg fat mass (right)	3.93	8	5	11.1	-0.66	7.7e-02	C6orf3 CADM2 CPSF4 GTF3C6 MAP2K5 NAT6 NPC1 STX1B
Leg fat mass (left)	3.93	9	5	11.1	-0.68	4.2e-02	C10orf32 C6orf3 CADM2 CPSF4 GTF3C6 MAP2K5 NAT6 NPC1 STX1B
Arm fat mass (left)	3.67	10	5	11.1	-0.55	1.0e-01	C6orf3 CADM2 CPSF4 GTF3C6 MAP2K5 NAT6 NOB1 NPC1 STX1B TMEM161B-AS1
Arm fat mass (right)	3.63	11	5	11.1	-0.47	1.5e-01	C6orf3 CADM2 CPSF4 GTF3C6 MAP2K5 NAT6 NOB1 NPC1 SRR STX1B TMEM161B-AS1
Waist circumference	3.57	9	4	8.9	-0.52	1.5e-01	C6orf3 CADM2 CPSF4 MAP2K5 NAT6 NOB1 NPC1 STX1B TMEM161B-AS1
Blood White Count	3.51	5	3	6.7	-0.93	2.2e-02	ATXN2 C10orf32 CPSF4 REST SRR
Diastolic blood pressure, automated reading	3.41	4	2	4.4	-0.74	2.6e-01	ATXN2 C10orf32 MAP2K5 SRR
Whole body fat mass	3.39	9	4	8.9	-0.47	2.0e-01	C6orf3 CADM2 CPSF4 GTF3C6 MAP2K5 NAT6 NPC1 STX1B TMEM161B-AS1
Hypothyroidism (self reported)	3.37	1	1	2.2	0.00	1.0e+00	ATXN2
Arm fat percentage (right)	3.30	11	3	6.7	-0.41	2.1e-01	C6orf3 CADM2 CPSF4 GTF3C6 MAP2K5 NAT6 NOB1 NPC1 SRR STX1B TMEM161B-AS1
Alcohol intake frequency.	3.29	4	2	4.4	0.90	9.5e-02	CADM2 NPC1 REST RP11-89K21.1
Leg fat percentage (left)	3.29	9	3	6.7	-0.67	4.7e-02	C6orf3 CADM2 CPSF4 GTF3C6 MAP2K5 NAT6 NPC1 RP5-1112D6.4 STX1B
Arm fat percentage (left)	3.28	11	3	6.7	-0.41	2.1e-01	C6orf3 CADM2 CPSF4 GTF3C6 MAP2K5 NAT6 NOB1 NPC1 SRR STX1B TMEM161B-AS1
Leg fat percentage (right)	3.20	9	3	6.7	-0.67	4.7e-02	C6orf3 CADM2 CPSF4 GTF3C6 MAP2K5 NAT6 NPC1 RP5-1112D6.4 STX1B
Long-standing illness, disability or infirmity	3.14	2	0	0.0	0.00	1.0e+00	GTF3C6 RP5-1112D6.4
Hip circumference	3.12	10	5	11.1	-0.40	2.5e-01	ATXN2 C10orf32 C6orf3 CADM2 CPSF4 MAP2K5 NAT6 NPC1 STX1B TMEM161B-AS1
Weight	3.10	9	4	8.9	-0.53	1.4e-01	C10orf32 C6orf3 CADM2 CPSF4 MAP2K5 NAT6 NPC1 STX1B TMEM161B-AS1
Hand grip strength (left)	3.09	5	2	4.4	-0.64	2.4e-01	C10orf32 CADM2 NOB1 PRPS1P2 TMEM180
Average weekly red wine intake	3.09	1	1	2.2	0.00	1.0e+00	NPC1
Medication: Levothyroxine sodium	3.07	1	1	2.2	0.00	1.0e+00	ATXN2
Body fat percentage	2.96	7	2	4.4	-0.37	4.1e-01	C6orf3 CPSF4 GTF3C6 MAP2K5 NPC1 STX1B TMEM161B-AS1
Impedance of arm (left)	2.93	7	2	4.4	0.94	1.5e-03	CADM2 CPSF4 MAP2K5 NAT6 REST STX1B TMEM180
Impedance of whole body	2.92	7	3	6.7	0.71	7.4e-02	CADM2 CPSF4 MAP2K5 NAT6 PRPS1P2 STX1B TMEM180
Body Mass Index (BMI) (2010)	2.90	2	1	2.2	0.00	1.0e+00	MAP2K5 NPC1
Hypothyroidism/myxoedema (self-reported)	2.90	1	1	2.2	0.00	1.0e+00	ATXN2
Systolic Blood Pressure	2.87	5	3	6.7	0.37	5.4e-01	ATXN2 CADM2 NCAM1 NOB1 SRR
Pain experienced in last month	2.87	3	0	0.0	0.00	1.0e+00	ATXN2 COMMD7 PRPS1P2
Trunk fat mass	2.85	8	2	4.4	-0.38	3.5e-01	C6orf3 CADM2 CPSF4 GTF3C6 MAP2K5 NPC1 STX1B TMEM161B-AS1
Impedance of arm (right)	2.85	5	2	4.4	0.93	2.2e-02	CADM2 CPSF4 MAP2K5 NAT6 STX1B
Vascular/heart problems diagnosed by doctor	2.83	4	2	4.4	0.85	1.5e-01	ATXN2 MAP2K5 SRR TMEM161B-AS1
Average weekly beer plus cider intake	2.82	3	0	0.0	0.00	1.0e+00	CADM2 NAT6 RP11-89K21.1
Age started oral contraceptive pill	2.82	2	0	0.0	0.00	1.0e+00	CADM2 NPC1
Age when periods started (menarche)	2.81	5	1	2.2	0.29	6.4e-01	MAP2K5 MSH6 NAT6 NOB1 PRPS1P2
Arm predicted mass (left)	2.75	10	4	8.9	-0.45	1.9e-01	ATXN2 C10orf32 CADM2 MAP2K5 NAT6 NPC1 PRPS1P2 REST STX1B TMEM180
Arm fat-free mass (left)	2.73	10	4	8.9	-0.46	1.9e-01	ATXN2 C10orf32 CADM2 MAP2K5 NAT6 NPC1 PRPS1P2 REST STX1B TMEM180
Arm fat-free mass (right)	2.69	10	5	11.1	-0.47	1.7e-01	ATXN2 C10orf32 CADM2 MAP2K5 NAT6 NPC1 PRPS1P2 REST STX1B TMEM180
Reaction Time	2.67	2	1	2.2	0.00	1.0e+00	ATXN2 COMMD7
Arm predicted mass (right)	2.67	10	4	8.9	-0.47	1.7e-01	ATXN2 C10orf32 CADM2 MAP2K5 NAT6 NPC1 PRPS1P2 REST STX1B TMEM180
Impedance of leg (left)	2.65	10	3	6.7	0.17	6.4e-01	CADM2 COMMD7 CPSF4 MAP2K5 NAT6 NOB1 PRPS1P2 SDK1 SRR TMEM161B-AS1
Suffer from 'nerves'	2.65	1	1	2.2	0.00	1.0e+00	CADM2
Townsend deprivation index at recruitment	2.62	2	0	0.0	0.00	1.0e+00	MAP2K5 PRPS1P2
Heart attack	2.58	2	0	0.0	0.00	1.0e+00	ATXN2 NOB1
Impedance of leg (right)	2.57	10	4	8.9	0.21	5.7e-01	CADM2 COMMD7 CPSF4 MAP2K5 NAT6 NCAM1 NOB1 PRPS1P2 SRR TMEM161B-AS1
Number of children fathered	2.57	1	1	2.2	0.00	1.0e+00	CADM2
Trunk fat percentage	2.56	8	2	4.4	-0.40	3.2e-01	C6orf3 CPSF4 GTF3C6 MAP2K5 NOB1 NPC1 STX1B TMEM161B-AS1
High blood pressure	2.56	4	2	4.4	-0.79	2.1e-01	ATXN2 MAP2K5 SRR TMEM161B-AS1
Taking other prescription medications	2.48	1	1	2.2	0.00	1.0e+00	ATXN2
Heart attack/myocardial infarction (self-reported)	2.47	2	0	0.0	0.00	1.0e+00	ATXN2 NOB1
Cardiovascular Disease	2.46	4	2	4.4	0.00	1.0e+00	ATXN2 MAP2K5 NPC1 TMEM161B-AS1
Pulse wave reflection index	2.46	1	0	0.0	0.00	1.0e+00	NAT6
Leg predicted mass (left)	2.44	9	4	8.9	-0.34	3.8e-01	C10orf32 CADM2 MAP2K5 NAT6 NPC1 PRPS1P2 STX1B TMEM161B-AS1 TMEM180
Basal metabolic rate	2.43	9	5	11.1	-0.35	3.6e-01	ATXN2 C10orf32 CADM2 MAP2K5 NAT6 NPC1 PRPS1P2 STX1B TMEM180
Worry too long after embarrassment	2.42	2	0	0.0	0.00	1.0e+00	CADM2 MAP2K5
Leg fat-free mass (left)	2.41	9	4	8.9	-0.34	3.7e-01	C10orf32 CADM2 MAP2K5 NAT6 NPC1 PRPS1P2 STX1B TMEM161B-AS1 TMEM180
Qualifications: College or University degree	2.41	5	2	4.4	0.60	2.9e-01	C10orf32 CADM2 NAT6 NPC1 SDK1
Systolic blood pressure, automated reading	2.39	2	2	4.4	0.00	1.0e+00	ATXN2 SRR
Mean time to correctly identify matches	2.38	2	1	2.2	0.00	1.0e+00	ATXN2 COMMD7
Qualifications: NVQ or HND or HNC or equivalent	2.38	2	0	0.0	0.00	1.0e+00	ATXN2 SDK1
Hand grip strength (right)	2.34	4	1	2.2	0.12	8.8e-01	CADM2 NOB1 PRPS1P2 TMEM180
Hypertension (Self-reported)	2.34	3	1	2.2	0.00	1.0e+00	ATXN2 MAP2K5 SRR
Number of self-reported non-cancer illnesses	2.34	2	1	2.2	0.00	1.0e+00	ATXN2 MAP2K5
Exposure to tobacco smoke outside home	2.31	2	0	0.0	0.00	1.0e+00	C10orf32 NAT6
Alcohol intake versus 10 years previously	2.26	2	0	0.0	0.00	1.0e+00	C10orf32 NPC1
Medication: Blood pressure	2.26	1	1	2.2	0.00	1.0e+00	ATXN2
Number of full sisters	2.25	1	1	2.2	0.00	1.0e+00	CADM2
Whole body water mass	2.25	10	4	8.9	-0.43	2.1e-01	ATXN2 C10orf32 CADM2 MAP2K5 NAT6 NPC1 PRPS1P2 REST STX1B TMEM180
Leg fat-free mass (right)	2.23	9	3	6.7	-0.34	3.7e-01	C10orf32 CADM2 MAP2K5 NAT6 NPC1 PRPS1P2 STX1B TMEM161B-AS1 TMEM180
Leg predicted mass (right)	2.23	9	3	6.7	-0.34	3.7e-01	C10orf32 CADM2 MAP2K5 NAT6 NPC1 PRPS1P2 STX1B TMEM161B-AS1 TMEM180
Wears glasses or contact lenses	2.22	2	0	0.0	0.00	1.0e+00	CADM2 NPC1
Chronotype (morning person)	2.20	4	0	0.0	-0.02	9.8e-01	ATXN2 CPSF4 NCAM1 TMEM161B-AS1
Whole body fat-free mass	2.20	10	4	8.9	-0.44	2.0e-01	ATXN2 C10orf32 CADM2 MAP2K5 NAT6 NPC1 PRPS1P2 REST STX1B TMEM180
Medication for pain relief, constipation, heartburn	2.18	1	0	0.0	0.00	1.0e+00	COMMD7
Ulcerative Colitis	2.12	2	0	0.0	0.00	1.0e+00	C6orf3 COMMD7
Father's age at death	2.12	2	0	0.0	0.00	1.0e+00	ATXN2 CCDC167
Medication for cholesterol, blood pressure or diabetes	2.11	1	0	0.0	0.00	1.0e+00	ATXN2
Neuroticism	2.10	3	0	0.0	0.00	1.0e+00	CADM2 MAP2K5 PRPS1P2
Pulse rate	2.09	1	0	0.0	0.00	1.0e+00	NAT6
Forced expiratory volume in 1-second (FEV1), predicted percentage	2.08	3	0	0.0	0.00	1.0e+00	PRPS1P2 REST STX1B
Pulse rate, automated reading	2.07	4	1	2.2	0.57	4.3e-01	CPSF4 MSH6 NAT6 TMEM161B-AS1
Trunk fat-free mass	2.05	9	4	8.9	-0.44	2.4e-01	ATXN2 C10orf32 CADM2 MAP2K5 NAT6 NPC1 PRPS1P2 REST TMEM180
Number of live births	2.05	2	1	2.2	0.00	1.0e+00	CADM2 NAT6
Ulcerative Colitis (UC)	2.03	2	1	2.2	0.00	1.0e+00	C6orf3 NAT6
Trunk predicted mass	2.03	9	4	8.9	-0.43	2.5e-01	ATXN2 C10orf32 CADM2 MAP2K5 NAT6 NPC1 PRPS1P2 REST TMEM180
Number of treatments/medications taken	2.02	2	1	2.2	0.00	1.0e+00	ATXN2 COMMD7
Hearing difficulty/problems with background noise	2.02	1	0	0.0	0.00	1.0e+00	NPC1
Alcohol drinker status: Never	2.01	1	0	0.0	0.00	1.0e+00	CADM2
Forced expiratory volume in 1-second (FEV1)	2.00	4	2	4.4	0.48	5.2e-01	NOB1 PRPS1P2 REST RP11-89K21.1
Shortness of breath walking on level ground	2.00	1	0	0.0	0.00	1.0e+00	COMMD7
Number of full brothers	1.99	1	0	0.0	0.00	1.0e+00	CADM2
Medication: Atenolol	1.98	1	1	2.2	0.00	1.0e+00	ATXN2
Allergy or Eczema	1.92	5	0	0.0	0.69	1.9e-01	ATXN2 C10orf32 CPSF4 SRR TMEM180
Had other major operations	1.89	1	0	0.0	0.00	1.0e+00	NPC1
Overall health rating	1.88	2	0	0.0	0.00	1.0e+00	NPC1 PRPS1P2
Qualifications: CSEs or equivalent	1.86	1	0	0.0	0.00	1.0e+00	COMMD7
Lung FVC	1.85	7	4	8.9	0.04	9.3e-01	C6orf3 MAP2K5 MSH6 NOB1 PRPS1P2 REST STX1B
Mouth/teeth dental problems: Dentures	1.84	1	0	0.0	0.00	1.0e+00	NAT6
Loneliness, isolation	1.81	1	0	0.0	0.00	1.0e+00	KIAA1908
Type 2 Diabetes (T2D) (2018)	1.80	2	0	0.0	0.00	1.0e+00	ATXN2 CPSF4
Birth weight	1.80	2	1	2.2	0.00	1.0e+00	ATXN2 SRR
Peak expiratory flow (PEF)	1.78	3	1	2.2	0.00	1.0e+00	C10orf32 PRPS1P2 REST
Age at First Birth	1.77	1	0	0.0	0.00	1.0e+00	NAT6
Illnesses of siblings	1.77	1	0	0.0	0.00	1.0e+00	ATXN2
Hair/balding pattern: Pattern 4	1.77	3	1	2.2	0.00	1.0e+00	C6orf3 MSH6 SRR
Medication: Paracetamol	1.77	1	0	0.0	0.00	1.0e+00	COMMD7
Neuroticism score	1.76	1	0	0.0	0.00	1.0e+00	PRPS1P2
Blood Red Count	1.75	6	4	8.9	0.19	7.2e-01	ATXN2 COMMD7 GTF3C6 MAP2K5 NAT6 RP5-1112D6.4
Headache pain in last month	1.75	1	0	0.0	0.00	1.0e+00	MAP2K5
Lupus	1.74	2	0	0.0	0.00	1.0e+00	ATXN2 STX1B
Chronic bronchitis/emphysema (father)	1.74	1	0	0.0	0.00	1.0e+00	MAP2K5
Forced vital capacity (FVC)	1.74	4	1	2.2	-0.41	5.9e-01	C10orf32 NOB1 PRPS1P2 REST
Blood clot in the leg (DVT)	1.72	1	0	0.0	0.00	1.0e+00	ATXN2
Medication: Aspirin	1.72	1	0	0.0	0.00	1.0e+00	ATXN2
Qualifications: A levels/AS levels or equivalent	1.71	2	0	0.0	0.00	1.0e+00	CADM2 NAT6
Medication: Ramipril	1.70	2	0	0.0	0.00	1.0e+00	ATXN2 NPC1
Age at first live birth	1.68	1	0	0.0	0.00	1.0e+00	NAT6
Birth weight of first child	1.67	1	1	2.2	0.00	1.0e+00	ATXN2
Qualifications: nursing, teaching	1.67	2	0	0.0	0.00	1.0e+00	CADM2 SDK1
Schizophrenia (2018)	1.66	2	0	0.0	0.00	1.0e+00	C10orf32 TMEM180
Gout (self-reported)	1.66	1	0	0.0	0.00	1.0e+00	ATXN2
Medication: Blood pressure	1.65	1	1	2.2	0.00	1.0e+00	ATXN2
Medication: Allopurinol	1.63	1	0	0.0	0.00	1.0e+00	ATXN2
Commuting to job workplace: Public transport	1.62	1	0	0.0	0.00	1.0e+00	CADM2
Relative age of first facial hair	1.61	2	0	0.0	0.00	1.0e+00	NAT6 NPC1
Medication: Aspirin	1.61	1	0	0.0	0.00	1.0e+00	ATXN2
Forced expiratory volume in 1-second (FEV1), Best measure	1.60	3	0	0.0	0.00	1.0e+00	NOB1 PRPS1P2 REST
Age at last live birth	1.59	1	0	0.0	0.00	1.0e+00	NAT6
Primary Biliary Cirrhosis	1.57	1	0	0.0	0.00	1.0e+00	ATXN2
Seen a psychiatrist for nerves, anxiety, tension or depression	1.57	1	0	0.0	0.00	1.0e+00	PRPS1P2
Irritability	1.57	1	0	0.0	0.00	1.0e+00	C10orf32
Irritable Bowel Disease (IBD)	1.55	1	0	0.0	0.00	1.0e+00	C6orf3
HbA1C	1.55	1	0	0.0	0.00	1.0e+00	ATXN2
Coronary Artery Disease (CAD)	1.52	1	0	0.0	0.00	1.0e+00	ATXN2
Schizophrenia (2014)	1.52	2	0	0.0	0.00	1.0e+00	C10orf32 TMEM161B-AS1
Mouth/teeth dental problems: Loose teeth	1.52	1	0	0.0	0.00	1.0e+00	TMEM180
Friendships satisfaction	1.52	1	0	0.0	0.00	1.0e+00	NPC1
Qualifications: None of the above	1.50	1	0	0.0	0.00	1.0e+00	NAT6
Forced vital capacity (FVC), Best measure	1.47	4	0	0.0	0.59	4.1e-01	MSH6 NOB1 PRPS1P2 REST
Illnesses of father: None of the above (group 1)	1.46	1	0	0.0	0.00	1.0e+00	ATXN2
Depressed Affect (Nagel 2018)	1.45	2	0	0.0	0.00	1.0e+00	ATXN2 NCAM1
Bipolar Disorder or Schizophrenia	1.43	2	0	0.0	0.00	1.0e+00	C10orf32 TMEM180
Medication: Bendroflumethiazide	1.43	1	0	0.0	0.00	1.0e+00	ATXN2
Supplements: Fish oil (including cod liver oil)	1.42	1	0	0.0	0.00	1.0e+00	CPSF4
Angina	1.38	1	0	0.0	0.00	1.0e+00	NOB1
Mouth/teeth dental problems	1.38	1	0	0.0	0.00	1.0e+00	PRPS1P2
Heel T-Score	1.37	6	2	4.4	-0.53	2.8e-01	C10orf32 MSH6 NCAM1 NOB1 REST SRR
Tense / 'highly strung'	1.36	1	0	0.0	0.00	1.0e+00	CADM2
Medication for cholesterol	1.35	1	0	0.0	0.00	1.0e+00	ATXN2
Allergy	1.34	1	0	0.0	0.00	1.0e+00	SRR
Angina (self-reported)	1.33	1	0	0.0	0.00	1.0e+00	NOB1
Number of operations (self-reported)	1.33	1	0	0.0	0.00	1.0e+00	NAT6
Medication: Paracetamol	1.32	1	0	0.0	0.00	1.0e+00	COMMD7
Respiratory disease	1.29	1	0	0.0	0.00	1.0e+00	REST
Intelligence (Savage-Jansen 2018)	1.28	1	0	0.0	0.00	1.0e+00	NAT6
Heel bone mineral density (BMD) T-score, automated (right)	1.22	2	0	0.0	0.00	1.0e+00	NCAM1 REST
Miserableness	1.22	1	0	0.0	0.00	1.0e+00	NCAM1
LDL Cholesterol	1.21	1	1	2.2	0.00	1.0e+00	ATXN2
Waist Hip Ratio (WHR)	1.16	3	0	0.0	0.00	1.0e+00	MSH6 NAT6 PRPS1P2
Fed-up feelings	1.16	1	0	0.0	0.00	1.0e+00	ATXN2
Eye problems/disorders: Glaucoma	1.16	1	0	0.0	0.00	1.0e+00	MAP2K5
Heel bone mineral density (BMD) T-score, automated (left)	1.11	1	0	0.0	0.00	1.0e+00	REST
Mood swings	1.00	1	0	0.0	0.00	1.0e+00	ATXN2
Blood Platelet Count	0.99	11	3	6.7	-0.38	2.4e-01	ATXN2 C10orf32 COMMD7 CPSF4 MSH6 NOB1 REST STX1B TMEM161B-AS1 TMEM180 TMEM242
Number of incorrect matches in round	0.99	1	0	0.0	0.00	1.0e+00	C10orf32
Sensitivity / hurt feelings	0.98	1	0	0.0	0.00	1.0e+00	PRPS1P2
Forced expiratory volume in 1-second (FEV1), predicted	0.93	1	0	0.0	0.00	1.0e+00	SDK1
Lung FEV1/FVC ratio	0.87	3	0	0.0	0.00	1.0e+00	COMMD7 MSH6 REST
Comparative height size at age 10	0.83	3	0	0.0	0.00	1.0e+00	ATXN2 NAT6 TMEM180
Sitting height	0.82	5	0	0.0	-0.52	3.7e-01	C10orf32 CPSF4 NCAM1 PRPS1P2 TMEM180
Height	0.78	12	3	6.7	-0.17	6.0e-01	ATXN2 C10orf32 C6orf3 CCDC167 CPSF4 NAT6 NCAM1 NOB1 PRPS1P2 REST SRR TMEM180
Standing height	0.78	6	1	2.2	-0.15	7.8e-01	ATXN2 C10orf32 CPSF4 NCAM1 PRPS1P2 TMEM180
Tanning	0.73	4	1	2.2	-0.95	4.6e-02	ATXN2 CADM2 COMMD7 KIAA1908
Hair Pigment	0.17	3	0	0.0	0.00	1.0e+00	ATXN2 MSH6 REST

Associations by panel

study	tissue	# hits	% hits/tests	avg chisq
GTEx	Brain Cerebellar Hemisphere	2	0.134	2.1
GTEx	Brain Cerebellum	7	0.353	2.1
GTEx	Brain Cortex	1	0.097	2.1
GTEx	Brain Hippocampus	1	0.191	2.1
GTEx	Brain Hypothalamus	2	0.339	2.1
GTEx	Ovary	0	0.000	2.1
GTEx	Adipose Visceral Omentum	2	0.098	2.0
GTEx	Artery Coronary	2	0.169	2.0
GTEx	Brain Frontal Cortex BA9	0	0.000	2.0
GTEx	Breast Mammary Tissue	0	0.000	2.0
GTEx	Cells EBV-transformed lymphocytes	2	0.141	2.0
GTEx	Colon Transverse	1	0.048	2.0
GTEx	Liver	2	0.279	2.0
GTEx	Lung	1	0.035	2.0
GTEx	Pancreas	1	0.061	2.0
GTEx	Pituitary	1	0.090	2.0
GTEx	Prostate	1	0.120	2.0
GTEx	Skin Not Sun Exposed Suprapubic	0	0.000	2.0
GTEx	Small Intestine Terminal Ileum	0	0.000	2.0
GTEx	Spleen	1	0.071	2.0
GTEx	Uterus	1	0.176	2.0
GTEx	Whole Blood	0	0.000	2.0
GTEx	Adipose Subcutaneous	4	0.115	1.9
GTEx	Artery Aorta	1	0.034	1.9
GTEx	Artery Tibial	5	0.133	1.9
GTEx	Brain Caudate basal ganglia	0	0.000	1.9
GTEx	Brain Nucleus accumbens basal ganglia	1	0.116	1.9
GTEx	Breast Mammary Tissue (Female)	1	0.061	1.9
GTEx	Cells Transformed fibroblasts	1	0.024	1.9
GTEx	Colon Sigmoid	0	0.000	1.9
GTEx	Esophagus Gastroesophageal Junction	1	0.069	1.9
GTEx	Esophagus Muscularis	3	0.093	1.9
GTEx	Heart Atrial Appendage	1	0.063	1.9
GTEx	Heart Left Ventricle	1	0.065	1.9
GTEx	Muscle Skeletal	3	0.104	1.9
GTEx	Nerve Tibial	3	0.069	1.9
GTEx	Skin Sun Exposed Lower leg	4	0.110	1.9
GTEx	Stomach	1	0.069	1.9
GTEx	Testis	2	0.063	1.9
GTEx	Thyroid	2	0.050	1.9
GTEx	Adrenal Gland	1	0.069	1.8
GTEx	Breast Mammary Tissue (Male)	0	0.000	1.8
GTEx	Esophagus Mucosa	1	0.030	1.8
GTEx	Vagina	0	0.000	1.8
METSIM	Adipose	9	0.195	1.8
ROSMAP	Brain Pre-frontal Cortex	5	0.114	1.8
CommonMind	Brain Pre-frontal Cortex	11	0.205	1.8
The Cancer Genome Atlas	Cervical Squamous Cell Carcinoma	1	0.091	1.8
The Cancer Genome Atlas	Glioblastoma Multiforme	3	0.294	1.8
The Cancer Genome Atlas	Kidney Renal Papillary Cell Carcinoma	2	0.098	1.8
The Cancer Genome Atlas	Brain Lower Grade Glioma	4	0.093	1.8
The Cancer Genome Atlas	Ovarian Serous Cystadenocarcinoma	3	0.188	1.8
The Cancer Genome Atlas	Pancreatic Adenocarcinoma	3	0.181	1.8
The Cancer Genome Atlas	Pheochromocytoma and Paraganglioma	4	0.301	1.8
GTEx	Brain Putamen basal ganglia	0	0.000	1.7
NTR	Blood	5	0.208	1.7
YFS	Blood	1	0.022	1.7
The Cancer Genome Atlas	Bladder Urothelial Carcinoma	3	0.181	1.7
The Cancer Genome Atlas	Breast Invasive Carcinoma	4	0.091	1.7
The Cancer Genome Atlas	Colon Adenocarcinoma	3	0.145	1.7
The Cancer Genome Atlas	Esophageal Carcinoma	2	0.292	1.7
The Cancer Genome Atlas	Head and Neck Squamous Cell Carcinoma	3	0.110	1.7
The Cancer Genome Atlas	Kidney Renal Clear Cell Carcinoma	2	0.049	1.7
The Cancer Genome Atlas	Liver Hepatocellular Carcinoma	1	0.090	1.7
The Cancer Genome Atlas	Lung Adenocarcinoma	2	0.068	1.7
The Cancer Genome Atlas	Lung Squamous Cell Carcinoma	2	0.080	1.7
The Cancer Genome Atlas	Prostate Adenocarcinoma	3	0.065	1.7
The Cancer Genome Atlas	Soft Tissue Sarcoma	1	0.094	1.7
The Cancer Genome Atlas	Stomach Adenocarcinoma	1	0.059	1.7
The Cancer Genome Atlas	Testicular Germ Cell Tumors	0	0.000	1.7
The Cancer Genome Atlas	Thyroid Carcinoma	7	0.136	1.7
The Cancer Genome Atlas	Rectum Adenocarcinoma	1	0.145	1.6
The Cancer Genome Atlas	Skin Cutaneous Melanoma	0	0.000	1.6
The Cancer Genome Atlas	Uterine Corpus Endometrial Carcinoma	0	0.000	1.4